Effectiveness of medical device class 3 HAIRCARE in treatments androgenetic alopecia

Comparison of the efficacy and safety of mesotherapy and meso-needling With HAIRCARE medical device class 3 REVITACARE brand in the treatment of male and female pattern androgenic alopecia: A double blinded controlled randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230401057792N1

Enrollment

Registered

2023-04-17

Start date

2023-05-15

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenic alopecia. Androgenic alopecia

Interventions

Intervention 1: Control group: The control group is treated with Haircare ( medical device class 3 ) in the amount of 2.5 cc in the form of mesotherapy. To perform mesotherapy, XylaP topical anestheti

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Men and women with hereditary hormonal hair loss

Exclusion criteria

Exclusion criteria: Severe allergic reaction to the injection Receiving any topical or systemic medication in the last 3 months for hair loss

Design outcomes

Primary

Measure	Time frame
The thickness of the hair. Timepoint: The third and sixth sessions and one month after the end of the treatment. Method of measurement: by the hair analyzer.;Hair density. Timepoint: The third and sixth sessions and one month after the end of the treatment. Method of measurement: by the hair analyzer.	—

Secondary

Measure	Time frame
Patient satisfaction score of treatment. Timepoint: After the third and sixth sessions and one month after the treatment. Method of measurement: Based on patient global assessment score.;Doctor's satisfaction. Timepoint: After the third and sixth sessions and one month after the treatment. Method of measurement: Based on Physician global assessment score.;Tolerability of treatment. Timepoint: during treatment. Method of measurement: questionnaire.	—

Measure

Time frame

Patient satisfaction score of treatment. Timepoint: After the third and sixth sessions and one month after the treatment. Method of measurement: Based on patient global assessment score.;Doctor's satisfaction. Timepoint: After the third and sixth sessions and one month after the treatment. Method of measurement: Based on Physician global assessment score.;Tolerability of treatment. Timepoint: during treatment. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Goodarzi

Iran University of Medical Sciences

goodarzi.a@iums.ac.ir+98 21 86701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026